21:21 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Vertex discontinues development of spinal cord injury compound VX-210

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) discontinued development of acute spinal cord injury candidate VX-210 after a DSMB recommended stopping a Phase IIb trial for futility following an interim analysis. Vertex has rights to VX-210 from BioAxone...
22:09 , Apr 12, 2018 |  BC Extra  |  Company News

Management tracks: Verona, Medigene, NeoPhore

Respiratory disease company Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) said CMO Kenneth Newman will resign, effective April 30. The company is seeking a successor. Cancer immunotherapy company Medigene AG (Xetra:MDG1) said CMO and SVP Kai Pinkernell...